Trust Signals
Written by the FormBlends Medical Team. All clinical claims are traced to named, peer-reviewed sources. Evidence is graded by study type. Speculative claims are labeled as such. This page does not constitute medical advice and does not promote off-label use.
Key Takeaways
- Tesamorelin is a 44-amino-acid GHRH analog with an FDA-approved indication (HIV lipodystrophy) supported by Phase 3 RCT data; sermorelin is a 29-amino-acid fragment with no current FDA approval and no Phase 3 body composition trial.
- In the Falutz et al. Phase 3 trials (2010, New England Journal of Medicine), tesamorelin at 2 mg/day reduced trunk fat area by roughly 15 to 18 percent over 26 weeks versus placebo.
- Sermorelin's half-life is approximately 10 to 20 minutes; tesamorelin's trans-3-hexenoic acid modification extends receptor binding stability but not dramatically its plasma half-life.
- Both peptides are contraindicated in active malignancy and require monitoring of IGF-1 and fasting glucose.
- Compounded sermorelin from U.S. pharmacies costs substantially less than branded tesamorelin (Egrifta), but compounded formulations carry purity and sterility risks that branded products do not.
What Is the Short Answer?
Sermorelin peptide and tesamorelin peptide are both GHRH analogs that stimulate pituitary GH release, but they differ in structure, evidence quality, and regulatory status. Tesamorelin has the stronger clinical record, an FDA-approved indication, and Phase 3 RCT data. Sermorelin has more accessible cost and compounding availability, but weaker evidence for body composition outcomes in healthy adults.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How do their structures differ, and why does that matter?
- What is the mechanism and what do real numbers show?
- What does the evidence ledger actually say?
- Honest head-to-head comparison table
- What most pages get wrong about these two peptides
- Why the storage and stability rules exist
- What are the real safety signals?
- Operational and label literacy: how to evaluate a product or protocol
- How do they compare to direct GH and other alternatives?
- FAQ
- Sources
- Footer Disclaimers
How Do Their Structures Differ, and Why Does That Matter?
Endogenous growth hormone releasing hormone (GHRH) is a 44-amino-acid peptide produced by the hypothalamus. Biological activity resides in the N-terminal 29 residues.
Sermorelin is GHRH(1-29)-NH2: the first 29 amino acids of native GHRH with an amidated C-terminus. It is the shortest GHRH fragment that retains full receptor agonist activity at the pituitary GHRH receptor (GHRHR). Because it lacks residues 30 to 44, it is smaller and cleared faster, with a plasma half-life of roughly 10 to 20 minutes in published pharmacokinetic data.
Tesamorelin is the full 44-amino-acid GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification was designed to resist dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary rapid inactivation pathway for native GHRH. The result is a molecule with greater metabolic stability and, in practice, a more sustained GH-stimulating effect per injection than sermorelin at comparable doses.
What Is the Mechanism and What Do Real Numbers Show?
Both peptides bind the pituitary GHRH receptor (a G-protein-coupled receptor), activating adenylyl cyclase, raising intracellular cAMP, and triggering pulsatile GH secretion. GH then stimulates hepatic IGF-1 production, which mediates most downstream anabolic and lipolytic effects.
Sermorelin pharmacokinetics (published data): Following subcutaneous injection, sermorelin produces a measurable GH pulse within 20 to 30 minutes. Peak serum GH responses in published stimulation testing studies have ranged widely depending on baseline GH status, age, and body composition. Published half-life estimates in adult pharmacokinetic studies are in the 10 to 20 minute range.
Tesamorelin clinical numbers from Falutz et al. (2010, NEJM):
- Study design: Two double-blind, placebo-controlled Phase 3 RCTs in HIV-positive adults with excess abdominal fat (combined n = approximately 816 across the two trials).
- Dose: 2 mg subcutaneously once daily.
- Primary outcome: Change in visceral adipose tissue (VAT) by CT scan at 26 weeks.
- Result: Tesamorelin reduced VAT by roughly 15 to 18 percent versus placebo.
- IGF-1 increased significantly in the treatment group, remaining within normal age-adjusted ranges in most participants.
- Reversal: VAT returned toward baseline within approximately 6 months of discontinuation, indicating the effect is not durable without continued dosing.
No equivalent Phase 3 trial exists for sermorelin in any adult body composition indication. The mechanistic rationale for sermorelin's body composition effects in healthy adults is biologically sound, but the clinical magnitude in that population is not established by high-quality trial data.
What Does the Evidence Ledger Actually Say?
| Claim | Best Evidence Type | Peptide | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | Phase 3 RCT (Falutz 2010, NEJM) | Tesamorelin | Positive (15 to 18% VAT reduction) | High |
| Stimulates pituitary GH release | Human pharmacokinetic and stimulation studies | Both | Positive | High |
| Raises serum IGF-1 | Multiple human trials | Both | Positive | High |
| Improves body composition in healthy adults | Small phase 2 studies, case series (sermorelin); small off-label studies (tesamorelin) | Both | Possibly positive; magnitude unclear | Low |
| Improves sleep quality | Small controlled study (Perras et al., sermorelin) | Sermorelin | Possibly positive for slow-wave sleep | Low |
| Reduces cardiovascular risk markers in HIV | Phase 3 secondary endpoint analysis | Tesamorelin | Mixed (triglycerides reduced; glucose mildly elevated) | Moderate |
| Anti-aging or longevity benefit | Mechanistic rationale only | Both | Unproven | Very Low |
| Durable body composition effect after stopping | Phase 3 follow-up data (tesamorelin) | Tesamorelin | Negative (effects reverse) | High |
Honest Head-to-Head Comparison Table
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Structure | GHRH(1-29)-NH2; 29 amino acids | Trans-3-hexenoic acid + GHRH(1-44); 44 amino acids |
| FDA approval | Withdrawn 2008 (pediatric GHD); no current approval | Approved 2010 (Egrifta) for HIV lipodystrophy |
| Strongest evidence | Phase 2 human GH stimulation; small sleep studies | Phase 3 RCT (Falutz 2010) for visceral fat |
| Typical clinical dose | 200 to 500 mcg SC nightly (off-label compounding) | 2 mg SC once daily (FDA-approved dose) |
| Plasma half-life | Roughly 10 to 20 minutes | Somewhat longer due to DPP-IV resistance; exact value varies by study |
| Availability | Compounded (U.S. licensed pharmacies) | Branded Egrifta; some compounding |
| Cost (approximate monthly) | Lower (compounded); rough range varies widely by pharmacy | High (branded); compounded versions exist at lower cost |
| Visceral fat reduction in non-HIV adults | Not established in RCTs | Not established in RCTs (off-label) |
| Where tesamorelin wins | Stronger evidence base, FDA-approval pathway, more complete receptor engagement | |
| Where sermorelin wins | Lower cost, longer compounding history in U.S., simpler molecule with decades of safety context | |
| Where both lose vs. alternatives | Neither is approved for healthy-adult anti-aging use; neither has durable off-treatment effects; neither outperforms lifestyle intervention in head-to-head data | |
What Most Pages Get Wrong About These Two Peptides
Most comparison pages treat tesamorelin's FDA approval as proof it works for general body composition or anti-aging. It does not. The approval is specifically for HIV-associated lipodystrophy, a condition defined by abnormal fat distribution linked to antiretroviral therapy. The mechanisms driving that condition are not identical to age-related changes in GH secretion in metabolically healthy adults.
Similarly, most pages cite sermorelin's historical FDA approval without noting that the branded product (Geref) was voluntarily withdrawn from the U.S. market by Serono in 2008 for commercial reasons, not safety reasons. This withdrawal means sermorelin now exists almost entirely through compounding pharmacies, outside the quality systems of an NDA-approved product. That is not automatically dangerous, but it is a real difference in quality assurance that commodity pages ignore.
A third commonly omitted point: the GH response to either peptide declines with age and with obesity. A 60-year-old with a BMI over 30 will have substantially blunted pituitary responsiveness compared to a lean 35-year-old. This is physiological, not a product quality issue, and it means the dose-response relationship varies considerably by patient.
Why the Storage and Stability Rules Exist
Peptides degrade through several pathways that determine every handling rule.
Lyophilized powder stability: Both sermorelin and tesamorelin are supplied as lyophilized (freeze-dried) powder because removing water dramatically slows hydrolysis, deamidation (asparagine and glutamine residues converting to aspartate and glutamate), and oxidation (methionine residues). At room temperature, water vapor in ambient air is enough to begin these reactions over days to weeks. Refrigeration at 2 to 8 degrees Celsius slows reaction rates. Freezing the lyophilized powder can extend shelf life further, but repeated freeze-thaw cycles damage peptide structure through ice crystal formation and concentration effects at the ice-liquid interface.
After reconstitution: Once dissolved in bacteriostatic water, hydrolysis resumes. The benzyl alcohol in bacteriostatic water retards microbial growth but does not stop chemical degradation. Most compounding pharmacy labels specify use within 30 days refrigerated after reconstitution. This is a conservative but chemically reasonable window, not an arbitrary rule. Using a degraded reconstituted peptide risks reduced potency and, if oxidation products accumulate, potential immunogenicity.
Why bacteriostatic water and not sterile water: Sterile water without preservative supports microbial growth once opened. Multi-dose vials used over weeks require bacteriostatic water to suppress contamination between draws. Single-use vials can use sterile water, but multi-dose subcutaneous use demands bacteriostatic.
Light sensitivity: Tryptophan and phenylalanine residues in peptides can undergo photo-oxidation under UV exposure, producing carbonyl species. Store vials in the original packaging or a dark drawer, not on an open countertop near a window.
What Are the Real Safety Signals?
Both peptides share a class-level safety profile because they share a mechanism.
- Fluid retention and edema: GH elevation increases renal sodium reabsorption via IGF-1-mediated effects. Peripheral edema and joint pain (arthralgias) are among the most commonly reported adverse effects in tesamorelin Phase 3 data.
- Glucose metabolism: GH is a counter-regulatory hormone that reduces insulin sensitivity. In Falutz et al., tesamorelin-treated patients showed modestly elevated fasting glucose. Neither peptide should be used without baseline and periodic HbA1c and fasting glucose monitoring, particularly in patients with pre-diabetes.
- IGF-1 elevation: Sustained supranormal IGF-1 is a theoretical cancer risk (elevated IGF-1 is associated with certain malignancy risks in epidemiological data). Both peptides are contraindicated in active malignancy. Monitoring IGF-1 within age- and sex-adjusted normal ranges is standard practice.
- Injection site reactions: Erythema, pruritus, and nodule formation are reported with both, particularly with compounded formulations where pH and osmolarity may be less tightly controlled than branded products.
- Hypothyroidism unmasking: Increased GH can accelerate conversion of T4 to the inactive reverse T3 in some individuals. Thyroid function should be checked at baseline if symptoms arise.
Operational and Label Literacy: How to Evaluate a Product or Protocol
Reading a Certificate of Analysis (COA) for either peptide:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| Identity testing | HPLC retention time match to reference standard AND/OR mass spectrometry confirmation of molecular weight | COA with only UV absorbance, no MS or HPLC identity confirmation |
| Purity by HPLC | Greater than or equal to 98 percent area under curve for the main peak | Purity below 95%, or purity stated without chromatogram data |
| Endotoxin | Below 10 EU/mg for injectables (USP 151 or LAL method) | No endotoxin test listed for an injectable product |
| Sterility | USP 71 sterility testing for compounded injectable vials | No sterility test, or only visual inspection claimed |
| Lot number and date | Specific lot traceable to batch records | Generic or undated COA, or a COA clearly reused across products |
Reconstitution math example for sermorelin at 9 mg/vial:
If a vial contains 9 mg (9,000 mcg) of sermorelin lyophilized powder and you add 3 mL of bacteriostatic water, concentration = 9,000 mcg divided by 3 mL = 3,000 mcg/mL. A 300 mcg dose requires 0.1 mL drawn in an insulin syringe. Check the vial label and pharmacy instructions because fill amounts vary. Never assume a standard concentration without verifying the vial mass and your reconstitution volume.
What a degraded product looks like: Discard if the reconstituted solution is visibly cloudy, contains particulates, or has a yellow or brown discoloration. A clear, colorless solution is expected. Cloudiness suggests aggregation or contamination. Color change suggests oxidation.
How Do They Compare to Direct GH and Other Alternatives?
| Intervention | Mechanism | Evidence Quality | Regulatory Status (U.S.) | Key Limitation |
|---|---|---|---|---|
| Sermorelin | GHRH receptor agonist; stimulates pulsatile GH | Phase 2 human; no Phase 3 for healthy adults | No current FDA approval; compounded | Evidence gap for off-label use |
| Tesamorelin | Stabilized GHRH analog; stimulates pulsatile GH | Phase 3 RCT for HIV lipodystrophy | FDA-approved for HIV lipodystrophy only | High cost; off-label for healthy adults is unvalidated |
| Recombinant human GH (somatropin) | Direct GH receptor agonist; bypasses pituitary | Multiple RCTs for approved GHD indications | FDA-approved for GHD, pediatric short stature, others | Supraphysiologic bolus; no pulse pattern; higher abuse potential; Schedule III precursor analog concerns; WADA prohibited |
| Ipamorelin / CJC-1295 | GH secretagogue receptor agonist (ghrelin receptor); often combined with GHRH analog | Small human pharmacology studies; no Phase 3 | No FDA approval; research compound | Even thinner human evidence base than sermorelin |
| Resistance exercise | Stimulates endogenous GH pulse amplitude | Multiple RCTs | No regulatory issues | Requires sustained behavior change; effects more modest than pharmacological intervention in GHD |
FAQ
What is the core difference between sermorelin and tesamorelin?
Sermorelin is a 29-amino-acid fragment of endogenous GHRH with a short half-life of roughly 10 to 20 minutes. Tesamorelin is a full 44-amino-acid GHRH analog stabilized with a trans-3-hexenoic acid group, giving it greater receptor binding stability and better clinical evidence for visceral fat reduction in HIV-associated lipodystrophy.
Which has stronger clinical evidence, sermorelin or tesamorelin?
Tesamorelin has two pivotal Phase 3 RCTs supporting its FDA approval for HIV-associated lipodystrophy. Sermorelin has Phase 2 human data on GH stimulation and some sleep quality data, but no Phase 3 trial and no FDA-approved indication for anti-aging or body composition in healthy adults.
Can sermorelin be used for anti-aging or growth hormone deficiency?
Sermorelin was FDA-approved for pediatric GH deficiency diagnosis and short stature treatment, but that approval was withdrawn in 2008 when Serono discontinued the product. It is now used off-label by compounding pharmacies, meaning evidence for anti-aging in healthy adults is limited to small studies and mechanistic rationale.
What does tesamorelin actually do to visceral fat?
In the Falutz et al. Phase 3 trials (2010, NEJM), tesamorelin at 2 mg/day subcutaneously reduced trunk fat area by roughly 15 to 18 percent versus placebo over 26 weeks in HIV-positive adults with lipodystrophy. The effect was largely reversed within 6 months of stopping treatment.
Is sermorelin safer than tesamorelin?
Both share the same class-level risks: fluid retention, injection site reactions, elevated IGF-1, and potential glucose dysregulation. Neither has a safety advantage established by head-to-head trial data. Tesamorelin's safety profile is better characterized simply because it has more rigorous published trial data.
How do you store and reconstitute sermorelin and tesamorelin?
Both peptides require refrigeration (2 to 8 degrees Celsius) as lyophilized powder and after reconstitution. Use bacteriostatic water for reconstitution. Once reconstituted, both should be used within the manufacturer or compounding pharmacy's specified window, typically 30 days refrigerated. Avoid freeze-thaw cycles, which accelerate peptide bond degradation.
What is the typical dosing protocol for each peptide?
Tesamorelin's FDA-approved dose is 2 mg subcutaneously once daily for HIV lipodystrophy. Sermorelin compounding protocols commonly use 200 to 500 mcg subcutaneously before sleep, but these doses lack Phase 3 validation. Any protocol should be supervised by a licensed prescribing clinician.
Will tesamorelin work for body composition in people without HIV?
There is limited evidence. Small studies have examined tesamorelin in non-HIV populations with abdominal adiposity, showing some visceral fat reduction, but no large RCT has validated this use. Off-label use lacks the safety and efficacy certainty of the approved HIV indication.
How does sermorelin compare to direct growth hormone injections?
Sermorelin stimulates the pituitary to release GH rather than bypassing it entirely. This preserves the natural GH pulse pattern and negative feedback loop, which theoretically reduces the risk of GH excess. Direct GH injection delivers a supraphysiologic bolus with no feedback regulation, giving it stronger acute IGF-1 elevation but higher risk profile.
Can these peptides cause cancer risk or worsen pre-existing tumors?
Both are contraindicated in patients with active malignancy because GH and IGF-1 elevation can theoretically promote tumor growth. This is a class-level contraindication shared by all GHRH analogs and exogenous GH. There is no RCT-level evidence quantifying the magnitude of this risk for either peptide specifically.
What does a Certificate of Analysis for these peptides need to show?
A credible COA should confirm identity by HPLC and/or mass spectrometry, purity above 98 percent by HPLC, endotoxin testing below USP limits (typically below 10 EU/mg for injectable peptides), and sterility testing for compounded injectable vials. Absence of any of these tests is a red flag.
Which peptide is more cost-effective?
Branded tesamorelin (Egrifta) carries a high monthly cost due to FDA approval and brand pricing. Compounded sermorelin from licensed pharmacies is substantially cheaper. However, compounded formulations carry regulatory and purity uncertainties that branded products do not, and cost comparisons must account for that risk difference.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information. 2010. Accessed via FDA.gov.
- Perras B, Collapsed-Marshall L, Born J, et al. Growth hormone secretagogues and sleep. Growth Hormone and IGF Research. 1999 (Perras B et al., Somatic and memory effects of growth hormone-releasing hormone in elderly subjects, Neuropsychopharmacology, 1999 Nov;21(5):627-37).
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- United States Pharmacopeia. General Chapter 71: Sterility Tests. USP-NF. Rockville, MD.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601-611. (Cited for GH secretagogue class context.)
- Signifor / Somavert prescribing information references for class-level GH axis contraindications. FDA.gov.
Footer Disclaimers
Platform: This page is published by FormBlends for informational and educational purposes only. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation. Consult a licensed healthcare provider before using any peptide or hormone-related product.
Research Compound / Compounded Medication: Sermorelin and tesamorelin, when obtained from compounding pharmacies, are not FDA-approved finished drug products. Their safety, purity, and potency are not evaluated by the FDA under the same standards as approved drugs. Tesamorelin as branded Egrifta is FDA-approved only for HIV-associated lipodystrophy. All other uses described on this page are off-label.
Results: Individual results vary. The clinical outcomes described in this article are from specific study populations (primarily HIV-positive adults) and may not apply to other populations. No guarantee of any specific result is made or implied.
Trademark: Egrifta is a registered trademark of Theratechnologies Inc. Geref was a registered trademark of Serono. All trademarks belong to their respective owners. FormBlends has no affiliation with these companies.